Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
7 "Woong-Ki Chung"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Breast cancer
The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim
Cancer Res Treat. 2022;54(4):1121-1129.   Published online December 31, 2021
DOI: https://doi.org/10.4143/crt.2021.1083
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods
We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results
Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion
The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.

Citations

Citations to this article as recorded by  
  • Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)
    Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C
    Breast Cancer Research and Treatment.2023; 200(1): 37.     CrossRef
  • 6,460 View
  • 185 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis
Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Cho, Chul Seung Kay, Yeon-Sil Kim
Cancer Res Treat. 2016;48(3):917-927.   Published online December 28, 2015
DOI: https://doi.org/10.4143/crt.2015.265
AbstractAbstract PDFPubReaderePub
Purpose
We compared the treatment results and toxicity in nasopharyngeal carcinoma (NPC) patients treated with concurrent chemotherapy (CCRT) alone (the CRT arm) or neoadjuvant chemotherapy followed by CCRT (the NCT arm). Materials and Methods A multi-institutional retrospective study was conducted to review NPC patterns of care and treatment outcome. Data of 568 NPC patients treated by CCRT alone or by neoadjuvant chemotherapy followed by CCRT were collected from 15 institutions. Patients in both treatment arms were matched using the propensity score matching method, and the clinical outcomes were analyzed.
Results
After matching, 300 patients (150 patients in each group) were selected for analysis. Higher 5-year locoregional failure-free survival was observed in the CRT arm (85% vs. 72%, p=0.014). No significant differences in distant failure-free survival (DFFS), disease-free survival (DFS), and overall survival were observed between groups. In subgroup analysis, the NCT arm showed superior DFFS and DFS in stage IV patients younger than 60 years. No significant difference in compliance and toxicity was observed between groups, except the radiation therapy duration was slightly shorter in the CRT arm (50.0 days vs. 53.9 days, p=0.018). Conclusion This study did not show the superiority of NCT followed by CCRT over CCRT alone. Because NCT could increase the risk of locoregional recurrences, it can only be considered in selected young patients with advanced stage IV disease. The role of NCT remains to be defined and should not be viewed as the standard of care.

Citations

Citations to this article as recorded by  
  • Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma
    Yihong Lin, Xiongbin Yu, Linbin Lu, Hong Chen, Junxian Wu, Yaying Chen, Qin Lin, Xuewen Wang, Xi Chen, Xiong Chen
    Cancer Biomarkers.2023; 37(1): 1.     CrossRef
  • Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis
    Shan-Shan Yang, Jian-Gui Guo, Jia-Ni Liu, Zhi-Qiao Liu, En-Ni Chen, Chun-Yan Chen, Pu-Yun OuYang, Fei Han, Fang-Yun Xie
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score‐matching studies
    Minmin Li, Bin Zhang, Qiuying Chen, Lu Zhang, Xiaokai Mo, Zhuozhi Chen, Zhe Jin, Luyan Chen, Jingjing You, Shuixing Zhang
    Head & Neck.2021; 43(6): 1912.     CrossRef
  • Longitudinal Assessment of Intravoxel Incoherent Motion Diffusion Weighted Imaging in Evaluating the Radio-sensitivity of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy
    Youping Xiao, Ying Chen, Yunbin Chen, Zhuangzhen He, Yiqi Yao, Jianji Pan
    Cancer Research and Treatment.2019; 51(1): 345.     CrossRef
  • Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management
    Yong Chan Ahn
    Radiation Oncology Journal.2019; 37(2): 67.     CrossRef
  • A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma
    Pu-Yun OuYang, Xiao-Min Zhang, Xing-Sheng Qiu, Zhi-Qiao Liu, Lixia Lu, Yuan-Hong Gao, Fang-Yun Xie
    The Oncologist.2019; 24(4): 505.     CrossRef
  • Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis
    Teng Hwee Tan, Yu Yang Soon, Timothy Cheo, Francis Ho, Lea Choung Wong, Jeremy Tey, Ivan W.K. Tham
    Radiotherapy and Oncology.2018; 129(1): 10.     CrossRef
  • Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
    Jiraporn Setakornnukul, Kullathorn Thephamongkhol
    BMC Cancer.2018;[Epub]     CrossRef
  • TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series
    N. Toumi, W. Ben Kridis, W. Mnejja, R. Bouzguenda, A. Khanfir, A. Ghorbel, J. Daoud, M. Frikha
    Cancer/Radiothérapie.2018; 22(3): 216.     CrossRef
  • Does concurrent chemoradiotherapy preceded by chemotherapy improve survival in locally advanced nasopharyngeal cancer patients? Experience from Ghana
    Joel Yarney, Naa A. Aryeetey, Alice Mensah, Emmanuel D. Kitcher, Verna Vanderpuye, Charles Aidoo, Kenneth Baidoo
    Cancers of the Head & Neck.2017;[Epub]     CrossRef
  • Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis
    Mei Lan, Chunyan Chen, Ying Huang, Li Tian, Zhijun Duan, Fei Han, Junfang Liao, Meiling Deng, Terence T. Sio, Anussara Prayongrat, Lie Zheng, Shaoxiong Wu, Taixiang Lu
    Scientific Reports.2017;[Epub]     CrossRef
  • A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma
    H. M. Li, P. Li, Y. J. Qian, X. Wu, L. Xie, F. Wang, H. Zhang, L. Liu
    BMC Cancer.2016;[Epub]     CrossRef
  • 13,166 View
  • 150 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
A Phase I/II Trial to Evaluate the Technical Feasibility of Partial Breast Irradiation with Three-Dimensional Conformal Radiation Therapy in Korean Women with Stage I Breast Carcinoma: An Initial Report of the Korean Radiation Therapy Oncology Group (KROG) Study 0804
Jae-Uk Jeong, Jung Han Yoon, Min Ho Park, Mee Sun Yoon, Ju-Young Song, Taek-Keun Nam, Woong-Ki Chung, Yong-Hyub Kim, Chang-Ok Suh, Sung-Ja Ahn
Cancer Res Treat. 2015;47(1):18-25.   Published online August 21, 2014
DOI: https://doi.org/10.4143/crt.2013.202
AbstractAbstract PDFPubReaderePub
Purpose
This prospective study was designed to verify the technical feasibility of partial breast irradiation in breast cancer patients with small breasts, which are commonly encountered in Korean women. Materials and Methods A total of 40 Gy, administered in 10 fractions on consecutive days (one fraction per day), was prescribed to the isocenters of the fields using three-dimensional conformal radiotherapy (3-DCRT). For all patients, treatment planning and dose parameters strictly adhered to the constraints set forth in the Radiation Therapy Oncology Group (RTOG) 0319 protocol. This study was designed such that if fewer than five of the first 42 evaluable patients received unacceptable scores, the treatment would be considered reproducible. Results Ten treatment plans (23.8%) were determined to have major variations. There was no major variation in planning target volume (PTV) coverage. The ipsilateral and contralateral breast dose limitations were not met in four (9.5%) and four cases (9.5%), respectively. Major variations in ipsilateral and contralateral lung dose limitations were observed in two cases (4.8%). Major variations in the heart and thyroid dose limitations were observed in one (2.4%) and one case (2.4%), respectively. In multivariate analysis, a ratio of PTV to ipsilateral breast volume (PTV/IB) > 0.16 was the only significant factor that statistically affected major variations. Conclusion We concluded that partial breast irradiation using 3-DCRT could not be reproduced in Korean breast cancer patients, particularly small-volumed breast surrogated as PTV/IB > 0.16. The dominant cause was the major variation in surrounding normal breast tissues.

Citations

Citations to this article as recorded by  
  • Assessment of Eligibility and Utilization of Accelerated Partial Breast Irradiation in Korean Breast Cancer Patients (KROG 22-15)
    Seok-Joo Chun, Ji Hwan Jo, Yong Bae Kim, Sangjoon Park, Sung-Ja Ahn, Su Ssan Kim, Kyubo Kim, Kyung Hwan Shin
    Cancer Research and Treatment.2024; 56(2): 549.     CrossRef
  • Intensity Modulated Radiotherapy and Volumetric Modulated Arc Therapy in the Treatment of Breast Cancer: An Updated Review
    Jee Suk Chang, Ji Hyun Chang, Nalee Kim, Yong Bae Kim, Kyung Hwan Shin, Kyubo Kim
    Journal of Breast Cancer.2022; 25(5): 349.     CrossRef
  • Who are the optimal candidates for partial breast irradiation?
    Ji Hyeon Joo, Yongkan Ki, Hosang Jeon, Dong Woon Kim, Jinhong Jung, Su Ssan Kim
    Asia-Pacific Journal of Clinical Oncology.2021; 17(4): 305.     CrossRef
  • First Experience in Korea of Stereotactic Partial Breast Irradiation for Low-Risk Early-Stage Breast Cancer
    Won Hee Lee, Jee Suk Chang, Min Jung Kim, Vivian Youngjean Park, Jung Hyun Yoon, Se Young Kim, Jee Ye Kim, Hyung Seok Park, Seung Il Kim, Young Up Cho, Byeong Woo Park, Yong Bae Kim
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • 12,653 View
  • 81 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
The Role of Radiotherapy in the Treatment of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Taek-Keun Nam, Jae-Sook Ahn, Yoo-Duk Choi, Jae-Uk Jeong, Yong-Hyeob Kim, Mee Sun Yoon, Ju-Young Song, Sung-Ja Ahn, Woong-Ki Chung
Cancer Res Treat. 2014;46(1):33-40.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.33
AbstractAbstract PDFPubReaderePub
PURPOSE
To assess radiotherapy for patients with early stage gastric mucosa-associated lymphoid tissue (MALT) lymphoma with respect to survival, treatment response, and complications.
MATERIALS AND METHODS
Enrolled into this study were 48 patients diagnosed with gastric MALT lymphoma from January 2000 to September 2012. Forty-one patients had low grade and seven had mixed component with high grade. Helicobacter pylori eradication was performed in 33 patients. Thirty-four patients received radiotherapy alone. Ten patients received chemotherapy before radiotherapy, and three patients underwent surgery followed by chemotherapy and radiotherapy. One patient received surgery followed by radiotherapy. All patients received radiotherapy of median dose of 30.6 Gy.
RESULTS
The duration of follow-up ranged from 6 to 158 months (median, 48 months). Five-year overall survival and cause-specific survival rates were 90.3% and 100%. All patients treated with radiotherapy alone achieved pathologic complete remission (pCR) in 31 of the low-grade and in three of the mixed-grade patients. All patients treated with chemotherapy and/or surgery prior to radiotherapy achieved pCR except one patient who received chemotherapy before radiotherapy. During the follow-up period, three patients developed diffuse large B-cell lymphoma in the stomach, and one developed gastric adenocarcinoma after radiotherapy. No grade 3 or higher acute or late complications developed. One patient, who initially exhibited gastroptosis, developed mild atrophy of left kidney.
CONCLUSION
These findings indicate that a modest dose of radiotherapy alone can achieve a high cure rate for low-grade and even mixed-grade gastric MALT lymphoma without serious toxicity. Patients should be carefully observed after radiotherapy to screen for secondary malignancies.

Citations

Citations to this article as recorded by  
  • Clinical Management of Patients with Gastric MALT Lymphoma: A Gastroenterologist’s Point of View
    Tamara Matysiak-Budnik, Kateryna Priadko, Céline Bossard, Nicolas Chapelle, Agnès Ruskoné-Fourmestraux
    Cancers.2023; 15(15): 3811.     CrossRef
  • Magnetic Resonance Imaging-Guided Radiation Therapy for Early-Stage Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
    Neris Dincer, Gamze Ugurluer, Gorkem Gungor, Teuta Zoto Mustafayev, Banu Atalar, Enis Ozyar
    Cureus.2022;[Epub]     CrossRef
  • Development and Validation of a Prognostic Nomogram for Gastric Marginal Zone Lymphoma: a Surveillance, Epidemiology and End Results-based population Study
    Mingliang Wang, Cheng Wu, Yida Lu, Xin Xu, Huizhen Wang, Youliang Wu, Xiaodong Wang, Yongxiang Li
    Future Oncology.2021; 17(5): 529.     CrossRef
  • Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma
    Laurent Quéro, Mouna Labidi, Marc Bollet, Côme Bommier, Sophie Guillerm, Christophe Hennequin, Catherine Thieblemont
    World Journal of Gastrointestinal Oncology.2021; 13(10): 1453.     CrossRef
  • Second Cancers in a Patient with Gastric MALT Lymphoma
    Lucy Navsaria, Alfonso Badillo, Michael Wang
    Case Reports in Medicine.2020; 2020: 1.     CrossRef
  • The Treatment of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma using Radiotherapy
    Aswin Nagarajan, Arun Sakthivelu, Alexander John, Ramya Ravichandar
    Indian Journal of Medical and Paediatric Oncology.2020; 41(04): 559.     CrossRef
  • Favorable radiation field decrease in gastric marginal zone lymphoma
    Gabriele Reinartz, Regina P. Pyra, Georg Lenz, Rüdiger Liersch, Georg Stüben, Oliver Micke, Kay Willborn, Clemens F. Hess, Andreas Probst, Rainer Fietkau, Ralf Jany, Jürgen Schultze, Christian Rübe, Carsten Hirt, Wolfgang Fischbach, Martin Bentz, Severin
    Strahlentherapie und Onkologie.2019; 195(6): 544.     CrossRef
  • Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma
    Anne-Laure Rentien, Michaël Lévy, Christiane Copie-Bergman, Charlotte Gagniere, Jehan Dupuis, Yann Le Baleur, Karim Belhadj, Iradj Sobhani, Corinne Haioun, Jean-Charles Delchier, Aurelien Amiot
    Digestive and Liver Disease.2018; 50(2): 181.     CrossRef
  • Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH)
    Tamara Matysiak-Budnik, Bettina Fabiani, Christophe Hennequin, Catherine Thieblemont, Georgia Malamut, Guillaume Cadiot, Olivier Bouché, Agnès Ruskoné-Fourmestraux
    Digestive and Liver Disease.2018; 50(2): 124.     CrossRef
  • Place de la radiothérapie pour les lymphomes du mucosa-associated lymphoid tissue gastriques : résultats d’une étude rétrospective
    L. Ghorbal, A. Hdiji, H. Ben Salah, F. Elloumi, M. Frikha, M. Elloumi, J. Daoud
    Cancer/Radiothérapie.2018; 22(8): 763.     CrossRef
  • Les lymphomes gastro-intestinaux
    P. Jamet, T. Matysiak-Budnik, L. Brichet, A. Ruskoné-Fourmestraux
    Oncologie.2018; 20(5-6): 107.     CrossRef
  • Radiotherapy for localized gastric mucosa–associated lymphoid tissue lymphoma: long-term outcomes over 10 years
    Yu Ohkubo, Yoshihiro Saito, Hiroki Ushijima, Masahiro Onishi, Tomoko Kazumoto, Jun-ichi Saitoh, Nobuko Kubota, Hirofumi Kobayashi, Nobuo Maseki, Yu Nishimura, Masafumi Kurosumi
    Journal of Radiation Research.2017; 58(4): 537.     CrossRef
  • Place de la radiothérapie dans la prise en charge des lymphomes malins non hodgkiniens
    L. Gastaud, B. Rossignol, F. Peyrade, D. Ré, J. Thariat, A. Thyss, J. Doyen
    Cancer/Radiothérapie.2016; 20(3): 236.     CrossRef
  • Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin
    Susann Stollberg, Daniel Kämmerer, Elisa Neubauer, Stefan Schulz, Ingrid Simonitsch-Klupp, Barbara Kiesewetter, Markus Raderer, Amelie Lupp
    Journal of Cancer Research and Clinical Oncology.2016; 142(11): 2239.     CrossRef
  • Radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma: dose-volumetric analysis and its clinical implications
    Hyeon Woo Lim, Tae Hyun Kim, Il Ju Choi, Chan Gyoo Kim, Jong Yeul Lee, Soo Jeong Cho, Hyeon Seok Eom, Sung Ho Moon, Dae Yong Kim
    Radiation Oncology Journal.2016; 34(3): 193.     CrossRef
  • Refractory peptic ulceration following radiation therapy in primary gastric lymphoma: A report of two cases
    CHUNYAN ZENG, SHIWEN LUO, NONGHUA LV, YOUXIANG CHEN
    Oncology Letters.2015; 9(1): 63.     CrossRef
  • Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma: Results of a prospective study with a long term follow-up
    Agnès Ruskoné-Fourmestraux, Tamara Matysiak-Budnik, Bettina Fabiani, Pascale Cervera, Hedia Brixi, Karine Le Malicot, Isabelle Nion-Larmurier, Jean-Fançois Fléjou, Christophe Hennequin, Laurent Quéro
    Radiotherapy and Oncology.2015; 117(1): 178.     CrossRef
  • 13,130 View
  • 101 Download
  • 19 Web of Science
  • 17 Crossref
Close layer
The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer
Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim, Joon-Kyoo Lee, Deok-Hwan Yang, Yeo-Kyeoung Kim, Je-Jung Lee, Sang-Chul Lim, Hyeoung-Joon Kim, Woong-Ki Chung, Ik-Joo Chung
Cancer Res Treat. 2007;39(3):93-98.   Published online September 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.3.93
AbstractAbstract PDFPubReaderePub
Purpose

This study was performed to determine the feasibility and safety of the use of induction chemotherapy combined with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiation therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Materials and Methods

The patients, that were initially not treated for locally advanced SCCHN, underwent three cycles of induction chemotherapy every 3 weeks at a dose of 70 mg/m2 docetaxel D1, 75 mg/m2 cisplatin D1, 1000 mg/m2 5-FU D1-4, and subsequently received concurrent chemoradiation therapy.

Results

Forty-nine patients were enrolled in this study and forty-three of the patients completed the treatment. The median duration of follow-up was 18 months (range, 6~39 months). All of the patients had stage III (26.5%) or IV (73.5%) squamous cell carcinoma. After sequential therapy, a complete response and partial response was seen in 28 (65.2%) and 13 (30.2%) patients, respectively. The overall response rate was 95.4%. Overall survival and progression-free survival (PFS) at 2 years were 88.7% and 69.7%, respectively. Grade 3~4 neutropenia occurred in 42.2% of the patients and grade 4 thrombocytopenia in 1 cycle (0.7%). Two patients (4.1%) died during the induction chemotherapy due to pneumonia and a subdural hemorrhage, respectively. The group of patients over 65 years of age showed a significant lower dose intensity than that of patients under 65 years of age, but PFS was not significantly different between two groups (p=0.105).

Conclusion

TPF induction chemotherapy followed by concurrent chemoradiotherapy showed a high level of CR and moderate treatment-induced toxicity. Adequate dose modification in elderly patients should be considered to maintain efficacy and avoid treatment-related toxicity.

Citations

Citations to this article as recorded by  
  • Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial
    Yungan TAO, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marie-Christine Kaminsky, Alexandre Coutte, Marc Alfonsi, Benôit Calderon, Pierre Boisselier, Laurent Martin, Jessica Miroir, Jean-Francois Ramee, Jean-Pierre Delord, Floria
    European Journal of Cancer.2023; 183: 24.     CrossRef
  • Serum Levels of Stromal Cell-Derived Factor-1α and Vascular Endothelial Growth Factor Predict Clinical Outcomes in Head and Neck Squamous Cell Carcinoma Patients Receiving TPF Induction Chemotherapy
    Yen-Hao Chen, Chih-Yen Chien, Yu-Ming Wang, Shau-Hsuan Li
    Biomedicines.2022; 10(4): 803.     CrossRef
  • Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study
    Ching-Yun Hsieh, Ming-Yuh Lein, Shih-Neng Yang, Yao-Ching Wang, Yin-Jun Lin, Chen-Yuan Lin, Chun-Hung Hua, Ming-Hsul Tsai, Ching-Chan Lin
    BMC Cancer.2020;[Epub]     CrossRef
  • Neutrophil lymphocyte ratio is an independent prognosticator in patients with locally advanced head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
    Hsiang-Lan Lai, Yeh Tang, Chih-Yen Chien, Fu-Min Fang, Tai-Lin Huang, Tai-Jan Chiu, Shau-Hsuan Li
    Journal of Cancer Research and Practice.2019; 6(4): 170.     CrossRef
  • Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study
    Yoshiyuki Tsuchiya, Kentaro Ushijima, Tadahide Noguchi, Naruo Okada, Jun-ichi Hayasaka, Yoshinori Jinbu, Hitoshi Ando, Yoshiyuki Mori, Mikio Kusama, Akio Fujimura
    Chronobiology International.2018; 35(2): 289.     CrossRef
  • Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology
    D. Alterio, M. Cossu Rocca, W. Russell-Edu, S. Dicuonzo, G. Fanetti, G. Marvaso, L. Preda, S. Zorzi, E. Verri, F. Nole’, B. A. Jereczek-Fossa
    Medical Oncology.2017;[Epub]     CrossRef
  • Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma
    Kaname Sakuma, Ryuki Tamura, Shintaro Hanyu, Haruka Takahashi, Hideaki Sato, Takahiro Oneyama, Akira Yamaguchi, Akira Tanaka
    Molecular and Clinical Oncology.2017;[Epub]     CrossRef
  • Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
    Shau‐Hsuan Li, Wei‐Che Lin, Tai‐Lin Huang, Chang‐Han Chen, Tai‐Jan Chiu, Fu‐Min Fang, Wan‐Ting Huang, Cheng‐Ming Hsu, Sheng‐Dean Luo, Chi‐Chih Lai, Yan‐Ye Su, Hui‐Ching Chuang, Chih‐Yen Chien
    Head & Neck.2016;[Epub]     CrossRef
  • Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
    Yan-Ye Su, Chih-Yen Chien, Sheng-Dean Luo, Tai-Lin Huang, Wei-Che Lin, Fu-Min Fang, Tai-Jan Chiu, Yen-Hao Chen, Chi-Chih Lai, Cheng-Ming Hsu, Shau-Hsuan Li
    World Journal of Surgical Oncology.2016;[Epub]     CrossRef
  • Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma
    Hironori Cho, Suetaka Nishiike, Yoshifumi Yamamoto, Yukinori Takenaka, Susumu Nakahara, Toshimichi Yasui, Atsushi Hanamoto, Hidenori Inohara
    Auris Nasus Larynx.2015; 42(5): 396.     CrossRef
  • Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck
    Woo Kyun Bae, Jun Eul Hwang, Hyun Jeong Shim, Sang Hee Cho, Ki Hyeong Lee, Hye Suk Han, Eun-Kee Song, Hwan Jung Yun, In Sung Cho, Joon Kyoo Lee, Sang-Chul Lim, Woong-Ki Chung, Ik-Joo Chung
    BMC Cancer.2013;[Epub]     CrossRef
  • Adjuvant Postoperative Radiotherapy with or without Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Importance of Patient Selection for the Postoperative Chemoradiotherapy
    Jong Hoon Lee, Jin Ho Song, Sang Nam Lee, Jin Hyoung Kang, Min Sik Kim, Dong Il Sun, Yeon-Sil Kim
    Cancer Research and Treatment.2013; 45(1): 31.     CrossRef
  • A case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case
    Daisuke Iitaka, Atsushi Shiozaki, Hitoshi Fujiwara, Daisuke Ichikawa, Kazuma Okamoto, Shuhei Komatsu, Yasutoshi Murayama, Hisashi Ikoma, Yoshiaki Kuriu, Masayoshi Nakanishi, Toshiya Ochiai, Yukihito Kokuba, Teruhisa Sonoyama, Eigo Otsuji
    Surgery Today.2013; 43(5): 556.     CrossRef
  • Usefulness and Indication of Superselective Intra-arterial Chemotherapy via the Radial Artery for Advanced Head and Neck Cancer^|^mdash;a Indication for Inaccessible to Treatment with Seldingers Method^|^mdash;
    Junkichi Yokoyama, Shin Ito, Shinichi Ohba, Mitsuhisa Fujimaki, Katsuhisa Ikeda, Makoto Hanaguri
    Nippon Jibiinkoka Gakkai Kaiho.2012; 115(6): 625.     CrossRef
  • Examination on the Effect of Docetaxel Dilution Concentration on the Hypersensitivity Revelation Rate
    Tatsuya Hayama, Masatoshi Hayasaka, Mei Onuma, Toshimitsu Nakayama, Sadao Amano, Yoshikazu Yoshida
    Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences).2012; 38(9): 547.     CrossRef
  • Chemotherapy with Modified Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Metastatic Head and Neck Cancer
    Jen-Tsun Lin, Guam-Min Lai, Tung-Hao Chang, Mu-Tai Liu, Chu-Ping Bi, Jer-Wei Wang, Mu-Kuan Chen
    Advances in Therapy.2012; 29(1): 71.     CrossRef
  • Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue
    Minako Suzuki, Hiroshi Ishikawa, Akira Tanaka, Izumi Mataga
    Human Cell.2011; 24(1): 21.     CrossRef
  • 11,289 View
  • 66 Download
  • 17 Crossref
Close layer
Results of Curative Radiation Therapy with or without Chemotherapy for Stage III Unresectable Non-Small Cell Lung Cancer
Sung-Ja Ahn, Young-Chul Kim, Kyu-Sik Kim, Kyung-Ok Park, Woong-Ki Chung, Taek-Keun Nam, Byung-Sik Nah, Ju-Young Song, Mi-Sun Yoon
Cancer Res Treat. 2005;37(5):268-272.   Published online October 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.5.268
AbstractAbstract PDFPubReaderePub
Purpose

We retrospectively analyzed the patients who received curative radiotherapy for unresectable stage III NSCLC to investigate the impact of chemotherapy.

Materials and Methods

From 1998 to 2001, the records of 224 patients who completed curative radiotherapy for NSCLC were reviewed. There were 210 males and 14 females, and their median age was 64 years (range 38~83). 54 patients had stage IIIA disease and 170 patients had stage IIIB disease. Conventional radiotherapy was given and the radiation dose ranged from 50~70 Gy with a median of 60 Gy, and chemotherapy was combined for 116 patients (52%).

Results

The median survival, the 2-year, and 5-year actuarial survival rates of all 224 patients were 15 months, 30%, and 7%, respectively. The median survival of the patients with stage IIIA and IIIB disease were 21 months and 13 months, respectively (p=0.14). The median survival of patients who received chemoradiation was 18 months compared to 14 months for the patients who received RT alone (p=0.02). Among the chemoradiation group of patients, the median survival time of the patients who received 1 to 3 cycles of chemotherapy was 16 months and that for the patients who received more than 3 cycles was 22 months (p=0.07). We evaluated the effects of the timing of chemoradiation in 57 patients who received more than 3 cycles of chemotherapy. The median survival of the patients with the concurrent sequence was 25 months and that for the patients with the sequential chemotherapy was 19 months (p=0.81).

Conclusions

For advanced stage III non-small cell lung cancer patients who completed the curative radiotherapy, the addition of chemotherapy improved the survival compared to the patients who received radiotherapy alone.

Citations

Citations to this article as recorded by  
  • Treatment for Non-Small-Cell Lung Cancer and Circulating Tumor Cells
    Joel Mason, Benjamin Blyth, Michael P MacManus, Olga A Martin
    Lung Cancer Management.2017; 6(4): 129.     CrossRef
  • Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer
    Dong-Soo Lee, Yeon-Sil Kim, Jin-Hyoung Kang, Sang-Nam Lee, Young-Kyoun Kim, Myung-Im Ahn, Dae-Hee Han, Ie-Ryung Yoo, Young-Pil Wang, Jae-Gil Park, Sei-Chul Yoon, Hong-Seok Jang, Byung-Oak Choi
    Cancer Research and Treatment.2011; 43(1): 32.     CrossRef
  • 9,390 View
  • 66 Download
  • 2 Crossref
Close layer
Assessment of Tumor Regression by Consecutive Pelvic Magnetic Resonance Imaging and Dose Modification during High-Dose-Rate Brachytherapy for Carcinoma of the Uterine Cervix
Taek-Keun Nam, Byung-Sik Nah, Ho-Sun Choi, Woong-Ki Chung, Sung-Ja Ahn, Seok-Mo Kim, Ju-Young Song, Mi-Seon Yoon
Cancer Res Treat. 2005;37(3):157-164.   Published online June 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.3.157
AbstractAbstract PDFPubReaderePub
Purpose

To assess tumor regression, as determined by pelvic magnetic resonance imaging (MRI), and evaluate the efficacies and toxicities of the interim brachytherapy (BT) modification method, according to tumor regression during multi-fractionated high-dose-rate (HDR) BT for uterine cervical cancer.

Materials and Methods

Consecutive MRI studies were performed pre-radiotherapy (RT), pre-BT and during interfraction of BT (inter-BT) in 69 patients with cervical cancer. External beam radiotherapy (EBRT) was performed, using a 10 MV X-ray, in daily fraction of 1.8 Gy with 4-fields, 5 d/wk. Radiation was delivered up to 50.4 Gy, with midline shielding at around 30.6 Gy. Of all 69 patients, 50 received modified interim BT after checking the inter-BT MRI. The BT was delivered in two sessions; the first was composed of several 5 Gy fractions to point A, twice weekly, using three channel applicators. According to the three measured orthogonal diameters of the regressed tumor, based on inter-BT MR images, the initial BT plan was modified, with the second session consisting of a few fractions of less than 5 Gy to point A, using a cervical cylinder applicator.

Results

The numbers of patients in FIGO stages Ib, IIa, IIb and IIIb+IVa were 19 (27.5%), 18 (26.1%), 27 (39.2%) and 5 (7.2%), respectively. Our treatment characteristics were comparable to those from the literatures with respect to the biologically effective dose (BED) to point A, rectum and bladder as reference points. In the regression analysis a significant correlation was observed between tumor regression and the cumulative dose to point A on the follow-up MRI. Nearly 80% regression of the initial tumor volume occurred after 30.6 Gy of EBRT, and this increased to 90% after an additional 25 Gy in 5 fractions of BT, which corresponds to 73.6 Gy of cumulative BED10 to point A. The median total fraction number, and those at the first and second sessions of BT were 8 (5~10), 5 (3~7) and 3 (1~5), respectively. The median follow-up time was 53 months (range, 9~66 months). The 4-year disease-free survival rate of all patients was 86.8%. Six (8.7%) patients developed pelvic failures, but major late complications developed in only two (2.9%).

Conclusion

Our study shows that effective tumor control, equivalent survival and low rates of major complications can be achieved by modifying the fraction size during BT according to tumor regression, as determined by consecutive MR images. We recommend checking the follow-up MRI at a cumulative BED10 of around 65 Gy to point A, with the initial BT modified at a final booster BT session.

Citations

Citations to this article as recorded by  
  • Correlations of UICC tumor stage and tumor regression on T2-weighted MRI sequences during definitive radiotherapy of cervical cancer
    Florian Arend, Markus Oechsner, Clara B. Weidenbächer, Stephanie E. Combs, Kai J. Borm, Marciana N. Duma
    Tumori Journal.2021; 107(2): 139.     CrossRef
  • Target volume changes through high-dose-rate brachytherapy for cervical cancer when evaluated on high resolution (3.0 Tesla) magnetic resonance imaging
    Wenqing Sun, Sudershan K. Bhatia, Geraldine M. Jacobson, Ryan T. Flynn, Yusung Kim
    Practical Radiation Oncology.2012; 2(4): e101.     CrossRef
  • Metabolic Response of Lymph Nodes Immediately After RT Is Related With Survival Outcome of Patients With Pelvic Node-Positive Cervical Cancer Using Consecutive [18F]fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
    Mee Sun Yoon, Sung-Ja Ahn, Byung-Sik Nah, Woong-Ki Chung, Ho-Chun Song, Su Woong Yoo, Ju-Young Song, Jae-Uk Jeong, Taek-Keun Nam
    International Journal of Radiation Oncology*Biology*Physics.2012; 84(4): e491.     CrossRef
  • 11,010 View
  • 64 Download
  • 3 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP